​

Soleno Therapeutics (SLNO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SLNO Stock Forecast

Soleno Therapeutics (SLNO) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $105.20, with a high of $125.00 and a low of $60.00. This represents a 145.74% increase from the last price of $42.81.

- $30 $60 $90 $120 $150 High: $125 Avg: $105.2 Low: $60 Last Closed Price: $42.81

SLNO Stock Rating

Soleno Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 11 Strong Sell Sell Hold Buy Strong Buy

SLNO Price Target Upside V Benchmarks

TypeNameUpside
StockSoleno Therapeutics145.74%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4510
Avg Price Target$100.25$101.40$104.10
Last Closing Price$42.81$42.81$42.81
Upside/Downside134.17%136.86%143.17%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26211---13
Dec, 25211---13
Nov, 2539---12
Oct, 2538---11
Sep, 2537---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 20, 2026Derek ArchilaWells Fargo$114.00$42.48168.36%166.29%
Jan 20, 2026H.C. Wainwright$120.00$42.48182.49%180.31%
Jan 13, 2026Robert W. Baird$107.00$40.14166.57%149.94%
Jan 12, 2026Wolfe Research$60.00$41.8943.23%40.15%
Nov 05, 2025Derek ArchilaWells Fargo$106.00$63.8566.01%147.61%
Oct 07, 2025Goldman Sachs$125.00$58.45113.86%191.99%
Jul 11, 2025Brian SkorneyRobert W. Baird$121.00$81.5748.34%182.64%
Mar 28, 2025Debjit ChattopadhyayGuggenheim$81.00$70.2215.35%89.21%
Dec 02, 2024Raghuram SelvarajuH.C. Wainwright$70.00$50.9137.50%63.51%
Oct 01, 2024Dae Gon HaStifel Nicolaus$74.00$50.4946.56%72.86%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 20, 2026Wells FargoOverweightOverweighthold
Jan 20, 2026H.C. WainwrightBuyBuyhold
Jan 12, 2026Wolfe ResearchOutperformOutperformhold
Nov 05, 2025Wells FargoOverweightOverweighthold
Oct 07, 2025Goldman SachsBuyinitialise
Aug 18, 2025H.C. WainwrightBuyBuyhold
Aug 07, 2025Cowen & Co.BuyBuyhold
Jun 23, 2025Cowen & Co.Buyinitialise
Mar 28, 2025GuggenheimBuyBuyhold
Mar 27, 2025LaidlawBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-1 $3 $7 $11 $15 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.36$-4.38----
Avg Forecast$-2.47$-4.22$-2.60$-0.77$2.68$5.91
High Forecast$-2.32$-4.14$-2.05$0.89$4.36$12.24
Low Forecast$-2.86$-4.29$-3.30$-3.00$-1.48$-0.02
Surprise %-4.45%3.79%----

Revenue Forecast

$0 $200M $400M $600M $800M $1B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$5.63M$37.02M$158.76M$336.47M$535.04M
High Forecast-$10.26M$77.63M$289.45M$613.47M$975.51M
Low Forecast-$1.29M$10.84M$36.30M$76.94M$122.34M
Surprise %------

Net Income Forecast

$-200M $-110M $-20M $70M $160M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-38.99M$-175.85M----
Avg Forecast$-38.99M$-69.56M$-44.12M$-28.80M$23.75M$97.47M
High Forecast$-38.18M$-68.34M$-33.84M$14.68M$71.91M$201.78M
Low Forecast$-47.13M$-70.78M$-54.40M$-49.48M$-24.41M$-267.86K
Surprise %-152.81%----

SLNO Forecast FAQ

Is Soleno Therapeutics stock a buy?

Soleno Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Soleno Therapeutics is a favorable investment for most analysts.

What is Soleno Therapeutics's price target?

Soleno Therapeutics's price target, set by 11 Wall Street analysts, averages $105.2 over the next 12 months. The price target range spans from $60 at the low end to $125 at the high end, suggesting a potential 145.74% change from the previous closing price of $42.81.

How does Soleno Therapeutics stock forecast compare to its benchmarks?

Soleno Therapeutics's stock forecast shows a 145.74% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Soleno Therapeutics over the past three months?

  • January 2026: 15.38% Strong Buy, 84.62% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 15.38% Strong Buy, 84.62% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Soleno Therapeutics’s EPS forecast?

Soleno Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.6, marking a -40.64% decrease from the reported $-4.38 in 2024. Estimates for the following years are $-0.77 in 2026, $2.68 in 2027, and $5.91 in 2028.

What is Soleno Therapeutics’s revenue forecast?

Soleno Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $37.02M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $158.76M, followed by $336.47M for 2027, and $535.04M for 2028.

What is Soleno Therapeutics’s net income forecast?

Soleno Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-44.12M, representing a -74.91% decrease from the reported $-176M in 2024. Projections indicate $-28.801M in 2026, $23.75M in 2027, and $97.47M in 2028.